Clinical Trials

Moderna Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the first participants have been dosed in the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, the Company’s vaccine candidate against COVID-19, in children...

TrialScope, the global leader in clinical trial disclosure and transparency technology, recently added Alexion to its rapidly expanding roster of customers. Alexion joins the ranks of other industry leaders that rely on TrialScope Disclose™ to help manage global clinical trial...

The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa Therapeutics on the announcement of their Phase 1 final results for the AT-301 nasal spray being developed for COVID-19. Atossa...

Valneva SE, a specialty vaccine company focused on prevention of diseases with major unmet needs, and Pfizer Inc. announced initiation of study VLA15-221. The VLA15-221 study builds on previous positive Phase 2 studies, incorporates new dose regimens and is...

Veeva Systems announced that LSK Global Pharma Services Co. Ltd, a leading Korean contract research organization (CRO), has adopted Veeva Vault eTMF, Veeva Vault CTMS, and Veeva SiteVault Free. With Veeva Vault Clinical applications, LSK Global PS can streamline...

Regeneron Pharmaceuticals, Inc. announced detailed results from a Phase 2 proof-of-concept trial evaluating the investigational antibody cocktail REGN1908-1909 in cat-allergic patients with mild asthma. The trial met the primary endpoint of preventing early asthma reactions (EAR, defined as a...

Barriers and triumphs of an underserved patient group. It is undeniable that clinical trials for rare diseases are more challenging to design and execute. Unlike trials with more frequently occurring diseases, rare disease trials have a smaller number of eligible...